Related Experiment Video
Updated: May 7, 2026

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
Signature Search Polestar: a comprehensive drug repurposing method evaluation assistant for customized oncogenic
Jinbo Zhang1,2, Shunling Yuan1, Wen Cao1
1Department of Phytochemistry, School of Pharmacy, Second Military Medical University, Shanghai 200433, China.
Summary:
The burgeoning high-throughput technologies have led to a significant surge in the scale of pharmacotranscriptomic datasets, especially for oncology. Signature search methods (SSMs), utilizing oncogenic signatures formed by differentially expressed genes through sequencing, have been instrumental in anti-cancer drug screening and identifying mechanisms of action without relying on prior knowledge. However, various studies have found that different SSMs exhibit varying performance across pharmacotranscriptomic datasets. In addition, the size of the oncogenic signature can also significantly impact the result of drug repurposing. Therefore, finding the optimal SSMs and customized oncogenic signature for a specific disease remains a challenge. To address this, we introduce Signature Search Polestar (SSP), a webserver integrating the largest pharmacotranscriptomic datasets of anti-cancer drugs from LINCS L1000 with five state-of-the-art SSMs (XSum, CMap, GSEA, ZhangScore, XCos). SSP provides three main modules: Benchmark, Robustness, and Application. Benchmark uses two indices, Area Under the Curve and Enrichment Score, based on drug annotations to evaluate SSMs at different oncogenic signature sizes. Robustness, applicable when drug annotations are insufficient, uses a performance score based on drug self-retrieval for evaluation. Application provides three screening strategies, single method, SS_all, and SS_cross, allowing users to freely utilize optimal SSMs with tailored oncogenic signature for drug repurposing.
Availability And Implementation:
SSP is free at https://web.biotcm.net/SSP/. The current version of SSP is archived in https://doi.org/10.6084/m9.figshare.26524741.v1, allowing users to directly use or customize their own SSP webserver.
Insights
Signature Search Polestar (SSP) optimizes anti-cancer drug repurposing by evaluating signature search methods (SSMs) and oncogenic signatures. This tool helps identify the best methods and gene signatures for improved drug discovery in oncology.
Area of Science:
- Pharmacogenomics and Computational Biology
- Oncology Drug Discovery
- Bioinformatics Tools
Background:
- High-throughput technologies generate large pharmacotranscriptomic datasets, particularly in oncology.
- Signature search methods (SSMs) are crucial for anti-cancer drug screening and mechanism identification.
- Performance of SSMs and oncogenic signature size vary, posing challenges for drug repurposing.
Purpose of the Study:
- To develop an integrated webserver, Signature Search Polestar (SSP), for optimizing anti-cancer drug repurposing.
- To evaluate and compare the performance of state-of-the-art SSMs using extensive pharmacotranscriptomic data.
- To provide flexible strategies for utilizing optimal SSMs and customized oncogenic signatures.
Main Methods:
- SSP integrates the LINCS L1000 pharmacotranscriptomic dataset with five SSMs (XSum, CMap, GSEA, ZhangScore, XCos).
- The Benchmark module evaluates SSMs using Area Under the Curve and Enrichment Score based on drug annotations.
- The Robustness module uses a drug self-retrieval performance score when annotations are limited.
- The Application module offers single method, SS_all, and SS_cross screening strategies.
Main Results:
- SSP facilitates the evaluation of various SSMs across different oncogenic signature sizes.
- The tool enables robust performance assessment of SSMs even with limited drug annotations.
- SSP provides adaptable screening strategies for personalized drug repurposing.
Conclusions:
- SSP addresses the challenge of selecting optimal SSMs and oncogenic signatures for specific diseases.
- The webserver enhances the efficiency and accuracy of anti-cancer drug repurposing.
- SSP empowers researchers to leverage tailored approaches for novel therapeutic discoveries.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023